Healthcare / Drug Manufacturers - Specialty & GenericBSE
$543.85
-3.90 (-0.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.0B · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$26.2B
P/E
N/A
•EV/EBITDA
17.7x
↑ROE
-0.6%
↓Gross Margin
50.0%
↑Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-0.2%
FCF CAGR
+30.6%
FCF margin
7.3%
FCF / Net income
-13.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.69B · net income $-74.1M · FCF $1.00B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.69B | $13.69B | $12.84B | $12.38B | $13.79B |
| Net Income | $-74.1M | $-74.1M | $5.4M | $-5.67B | $-221.8M |
| EBITDA | $1.87B | $1.87B | $2.15B | $-2.85B | $1.50B |
| EPS | — | — | 0.14 | -148.51 | -5.68 |
| Gross Margin | 50.0% | 50.0% | 51.2% | 32.3% | 41.0% |
| Operating Margin | 6.4% | 6.4% | 8.3% | -16.0% | 2.4% |
| Net Margin | -0.5% | -0.5% | 0.0% | -45.8% | -1.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.73 | 1.08 | 0.68 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.00B | $1.00B | $1.73B | $678.1M | $449.4M |
| Returns | |||||
| ROE | -0.6% | -0.6% | 0.0% | -60.8% | -1.5% |
| Valuation | |||||
| P/E | — | — | 3676.79 | — | — |
| EV/EBITDA | 17.66 | 17.66 | 12.94 | — | 15.53 |
| P/B | 2.09 | 2.09 | 1.81 | 1.69 | 0.88 |
| Growth & Yield | |||||
| Revenue Growth | 6.6% | 6.6% | 3.7% | -10.2% | — |
| EPS Growth | — | — | 100.1% | -2515.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.14 → n/d
Residual
+13.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.